CPA
SYRS

Cowen Prime Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Cowen Prime Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$41 Hold
13
– – ﹤0.01% 228
2023
Q1 		$0 Buy
+13
New +$50 ﹤0.01% 226

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Cowen Prime Advisors's SYRS Position: Q2 2023 in Review

Cowen Prime Advisors held its Syros Pharmaceuticals, Inc. Common Stock (SYRS) position steady in Q2 2023 at 13 shares worth $41. The position accounts for ﹤0.01% of the portfolio, ranked #228.

Cowen Prime Advisors first reported a position in SYRS in Q1 2023 and has held it in 2 quarters since. 53 funds tracked by Wall St. Rank hold SYRS as of Q2 2023.

  • Cowen Prime Advisors held 13 shares of Syros Pharmaceuticals, Inc. Common Stock worth $41 as of Q2 2023.
  • Cowen Prime Advisors left its Syros Pharmaceuticals, Inc. Common Stock share count unchanged in Q2 2023.
  • Syros Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of Cowen Prime Advisors's portfolio in Q2 2023, its #228 holding.
  • Cowen Prime Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2023 and has held it in 2 quarters since.
  • 53 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Cowen Prime Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.